Williamstown, MA -- (SBWIRE) --02/07/2012 -- Original, respected and reliable market reports that provide critical business insights to the prospects for, and risks in, leading pharmaceutical markets.
Espicom's Pharmaceutical Market Outlook reports have been used by senior management in commerce and industry for 30 years. Why? Because our experienced team of researchers and analysts combine economic, scientific, demographic and language skills to produce an unmatched and critical evaluation of the operating environment for pharmaceutical companies.
View Full Report Details and Table of Contents
An unmatched level of intelligence sourcing
Our full time team of experts regularly access over 1,200 primary source information points in regulatory authorities, health organisations, statistics offices and industry. Much of the information in the Pharmaceutical Market Outlook reports is not readily available in English elsewhere. Espicom partners with the widely regarded Economist Intelligence Unit (EIU) to provide up-to-date economic data - a constant requirement in these rapidly changing times.
Detailed analysis & novel forecasts
Assembling comprehensive data is one thing, but our strength lies in its interpretation. What does it mean and what are the implications for operations and business development? Our analysis is second to none and the economic and market forecasts are built on solid research principles and continually assessed to reflect current and anticipated market conditions.
By 2016, the global pharmaceutical market, including pharmacy and hospital sales, is forecast to be worth around US$1.6 trillion at retail prices. High growth in emerging markets will leverage slow growth in developed markets. Cost-containment policies will be offset against market demands for more effective products. Health access will expand, due to increasing generic penetration.
The local market is the operating environment in which companies have to work. Domestic priorities set the agenda that affects a company's operations, therefore the prevailing macroenvironment needs to be both understood and planned for. In this way, pharmaceutical companies have strengthened their capabilities to increase sales in local and international markets.
Beyond BRIC markets
The USA will continue to be the first worldwide economy, but other emerging markets will perform well, led by China, India, Russia and Brazil. However, a second wave of emerging markets will arise, namely South Korea, Mexico, Turkey, Indonesia and Poland. In an environment which is becoming more regulated, pharmaceutical producers are re-aligning their global strategies.
Quality information = business confidence
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Pharmaceuticals research reports at Fast Market Research
You may also be interested in these related reports:
- Therapeutics for Memory and Cognition Disorders
- Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies
- Charles River Laboratories International, Inc. (CRL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- The Outlook for Pharmaceuticals in the Middle East and North Africa
- Cardiovascular Generic Drugs: Prospects and Opportunities to 2012
- Akorn, Inc (AKRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Generic Drugs: Global collaboration opportunities
- Trubion Pharmaceuticals, Inc. (TRBN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Autacoids and Related Drugs: Technologies and Global Markets
- GlaxoSmithKline plc (GSK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile